A First-in-Human PoC Study With BEN2293 in Patients With Mild to Moderate Atopic Dermatitis

Summary

A randomised, adaptive design, double-blind, placebo-controlled, first-in-human, two-part study to investigate the safety, tolerability, PK and preliminary efficacy of multiple topical doses of BEN2293 in patients with mild to moderate AD.

Timeline

Start

2020-10-14

Primary completion

2023-01-12

Completion

2023-01-26

Drugs

Indications